Breast Cancer Core Needle Biopsy Market Revenue to Attain USD 1.63 Bn by 2035

Published: 24 Dec 2025

Author: Precedence Research

Share:

Table of Content

1. Breast Cancer Core Needle Biopsy Market Revenue and Trends 2026 to 2035 2. What Are the Factors That Have a Significant Contribution to the Growth of the breast cancer core needle biopsy market? 3. Segment Insights 4. Regional Insights 5. Breast Cancer Core Needle Biopsy Market Coverage

Breast Cancer Core Needle Biopsy Market Revenue and Trends 2026 to 2035

The global breast cancer core needle biopsy market revenue was valued at USD 1.03 billion in 2025 and is expected to attain around USD 1.63 billion by 2035, growing at a CAGR of 4.72% during forecast period. This market is experiencing unprecedented growth, driven by the growing awareness of early diagnosis, significant investment in research and development, and rapid technological innovation.

What Are the Factors That Have a Significant Contribution to the Growth of the breast cancer core needle biopsy market?

The rapid technological advancements in imaging and biopsy technologies and the increasing incidence of breast cancer are the major drivers, accelerating the growth of the breast cancer core needle biopsy market during the forecast period.  For instance, according to a new analysis by the International Agency for Research on Cancer published in February 2025, Global breast cancer incidence is projected to rise by 38% and related deaths by 68% by 2050. The paper analysed the global burden of female breast cancer overall and by age group in 185 countries using the WHO database GLOBOCAN, and 10-year trends in incidence in 50 countries and mortality rates in 46 countries using the cancer incidence in five continents and the WHO mortality databases.

Additionally, the rising awareness of early detection significantly increases the demand for core needle biopsies, as early diagnosis can improve treatment outcomes. Core needle biopsies offer shorter recovery, less pain/discomfort, and fewer associated complications than traditional surgery. Such factors are expected to fuel the expansion of the breast cancer core needle biopsy market.

Segment Insights

• By technology, the ultrasound based breast biopsy segment held the largest market share of 58.6% in the breast cancer core needle biopsy market during 2025, owing to its real-time imaging and increasing preference for minimally invasive procedures. Ultrasound-based breast biopsy is a preferred first-line technique for accurately diagnosing breast lesions. An ultrasound-based breast biopsy is a minimally invasive procedure that uses real-time sound waves to help locate a lump or abnormality and remove a tissue sample for examination under a microscope.
• By end-user, the hospitals & diagnostic laboratories segment held a dominant market share in 2024. Hospitals are primary cancer care hubs for cancer screening, early detection, and treatment. Hospitals are equipped with imaging modalities such as MRI, ultrasound, and mammography for accurately guiding biopsies. Hospitals are home to the pathologists, radiologists, and surgeons trained in performing these complex procedures.

Regional Insights

North America holds the dominant share in the global breast cancer core needle biopsy market. The region’s leadership is attributed to its presence of sophisticated healthcare infrastructure, robust research capabilities, increasing patient awareness, rising prevalence of breast cancer, and increasing adoption of emerging technology like MRI-guided and AI-assisted techniques. Government & NGO Programs promoting awareness and early screening of symptoms. The U.S. is a major contributor to the market. The country has the presence of advanced healthcare system with access to innovative diagnostic technology and highly skilled healthcare professionals. Such a combination of factors is likely to fuel the expansion of the region in the coming years.

On the other hand, the Asia Pacific region is anticipated to grow at the fastest rate in the market during the forecast period. The fastest growth of the region is attributed to the developing healthcare infrastructure, rising incidence of breast cancer, a surge in R&D funding, a supportive government framework, increased awareness for early screening, and a growing demand for minimally invasive procedures. The rapid technological innovation, such as MRI-based breast biopsy, ultrasound-based breast biopsy, mammography-based breast biopsy, CT-based breast biopsy, and other image-based breast biopsy, is driving the expansion of the regional market. In addition, the rising number of hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies, and academic & research institutes is anticipated to propel the growth of the breast cancer core needle biopsy market.

Breast Cancer Core Needle Biopsy Market Coverage

Recent Developments

• In May 2025, Agendia, Inc., announced the FLEX Study at the ESMO Breast Cancer 2025. The FLEX Study is a prospective, real-world evidence, observational breast cancer study designed to correlate whole transcriptome gene expression in early-stage breast cancer with clinical outcomes and to evaluate how genomic insights can inform treatment decisions in early-stage breast cancer.(Source: https://www.businesswire.com)

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7239

You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344